Affymax (AFFY) Stock Price, News & Analysis

Company Overview

Affymax, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to address significant unmet medical needs. Founded in 1988 and headquartered in California’s Silicon Valley, the company has established a foundation in peptide and small molecule chemistry to drive innovation in areas such as hematology, oncology and rare diseases. Affymax utilizes a proprietary platform to generate new molecular entities, aiming to advance candidates from early-stage discovery through clinical development.

The company’s research efforts have yielded a diverse pipeline of product candidates, including agents designed to stimulate red blood cell production, modulate the immune system and target oncogenic pathways. Affymax has also been involved in strategic partnerships with global pharmaceutical and biotechnology firms, enabling co-development opportunities that leverage its core expertise in medicinal chemistry and clinical trial management. These collaborations support the advancement of select molecules toward regulatory review and potential commercialization in multiple territories.

Affymax operates research facilities in California and maintains strategic alliances across North America, Europe and Asia to conduct clinical trials and regulatory interactions. By engaging with leading academic institutions and contract research organizations, the company enhances its capacity to generate clinical data and accelerate the assessment of safety and efficacy for its most promising candidates. This global network also facilitates access to patient populations in diverse therapeutic areas.

The leadership team at Affymax brings decades of experience in biopharmaceutical development, clinical operations and strategic licensing. Guided by a board of directors with deep roots in drug discovery and commercialization, the management group is committed to advancing the company’s pipeline and creating long-term value through scientific innovation and disciplined development practices.

Key Stats

• Today's Range: $0.0008 to $0.0008
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0024
• Volume: 8,861 shs
• Average Volume: 12,122 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AFFY Stock Analysis - Frequently Asked Questions

How have AFFY shares performed this year?

Affymax's stock was trading at $0.0008 at the beginning of 2025. Since then, AFFY stock has increased by 0.0% and is now trading at $0.0008.

How do I buy shares of Affymax?

Shares of AFFY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Affymax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Affymax investors own include Greenland Minerals (GGG), Golden Peak Minerals Inc.. (GRM), (MCPIQ) (MCPIQ), Bank of America (BAC), Boeing (BA), American Express (AXP) and Aurinia Pharmaceuticals (AUPH).

Company Calendar

• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:AFFY
• CIK: 1158223
• Web: www.affymax.com
• Phone: (650) 812-8700
• Fax: 650-424-0832
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 7.34